Phase­Bio touts 'break­through' badge for blood­thin­ner re­ver­sal agent li­censed from As­traZeneca, shares leap

At Phase­Bio, the game plan has been to hus­tle its Bril­in­ta re­ver­sal agent, PB2452, down what it sees as a short path to ap­proval, un­lock­ing rev­enue that will then fund more ex­pen­sive tri­als of its pul­monary ar­te­r­i­al hy­per­ten­sion drug. With a new break­through ther­a­py des­ig­na­tion, ex­ecs are march­ing on­ward with boost­ed con­fi­dence.

The “break­through” badge was be­stowed based on Phase I re­sults in which PB2452 achieved “im­me­di­ate and sus­tained re­ver­sal” of Bril­in­ta’s an­tiplatelet ef­fects. The biotech’s shares $PHAS surged 30%, reach­ing $16.4 pre-mar­ket.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER